NeuBase Therapeutics Inc.(NBSE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NBSE NeuBase Therapeutics Inc.

Not Yet Opened 11-25 16:00:00 EST

0.3780

+0.0000

0.00%

High0.3780	Low0.3780	Vol0.00
Open0.3780	D1 Closing0.3780	Amplitude0.00%
Mkt Cap1.42M	Tradable Cap1.26M	Total Shares3.75M
T/O0.00	T/O Rate0.00%	Tradable Shares3.32M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"NBSE","market":"US","secType":"STK","nameCN":"NeuBase Therapeutics Inc.","latestPrice":0.378,"timestamp":1732568400000,"preClose":0.378,"halted":0,"volume":0,"delay":0,"floatShares":3320901,"shares":3751590,"eps":-15.008684,"marketStatus":"Not Yet Opened","change":0,"latestTime":"11-25 16:00:00 EST","open":0.378,"high":0.378,"low":0.378,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-15.008684,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732611600000},"marketStatusCode":0,"adr":0,"listingDate":1371096000000,"exchange":"NASDAQ","adjPreClose":0.378,"volumeRatio":0,"impliedVol":1.5798,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/NBSE/wiki","defaultTab":"wiki","newsList":[{"id":"2441701180","title":"Tracking David Einhorn's Greenlight Capital Portfolio - Q1 2024 Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2441701180","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2441701180?lang=en_us&edition=fundamental","pubTime":"2024-06-07 10:23","pubTimestamp":1717727021,"startTime":"0","endTime":"0","summary":"Greenlight Capital's 13F portfolio value increased from $2.05B to $2.18B in Q1 2024.New stakes include Penn Entertainment, HP Inc., Roivant Sciences, and Liberty Global.Stake disposals include Gulfpor","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4697922-david-einhorn-greenlight-capital-portfolio-q1-2024-update","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["AER","BK4089","HPQ","LU0566484027.USD","BHF","DHT","LU1989771016.USD","LU1559883803.SGD","BK4179","ODP","LU2092937221.SGD","IE00B3S45H60.SGD","IE00B66KJ199.SGD","BK4082","KD","SDRL","GPK","BK4104","TLIS","IE0031619046.USD","CEIX","GLRE","MET","LU0648000940.SGD","LU1989772840.SGD","VTRS","GLD","XAR","BK4156","BK4088","LU1989772923.USD","BK4162","PPA","FCNCA","GPOR","PENN","NPWR","HRI","KVUE","LBTYA","NYCB","NBSE","FHN","ALIT","WFRD","LIVN","ROIV","THC","TECK","GRBK"],"gpt_icon":0},{"id":"2432131147","title":"BRIEF-Neubase Therapeutics, On May 2, Was Notified By Nasdaq On Not Regained Compliance With Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2432131147","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2432131147?lang=en_us&edition=fundamental","pubTime":"2024-05-04 04:35","pubTimestamp":1714768523,"startTime":"0","endTime":"0","summary":"May 3  - NeuBase Therapeutics Inc   :   * NEUBASE THERAPEUTICS INC -  ON MAY 2, NASDAQ NOTIFIED COMPANY THAT IT HAS NOT REGAINED COMPLIANCE WITH MINIMUM BID PRICE REQUIREMENT   * NEUBASE THERAPEUTICS -  EXPECTS TRADING IN CO'S COMMON STOCK WILL BE SUSPENDED UPON OPENING OF BUSINESS ON MAY 13Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585",".IXIC","ON","LENZ","LU1548497426.USD","BK4588","LU2210150020.SGD","LU2357305700.SGD","TQQQ","QID","LU0348723411.USD","BK4139","NDAQ","QQQ","NQmain","LU1861215975.USD","LU1861220033.SGD","QLD","LU1720051108.HKD","SQQQ","LU2095319765.USD","PSQ","LU1720051017.SGD","BK4141","BK4512","MNQmain","LU1854103824.USD","LU2210149790.SGD","BK4112","LU1854104046.USD","NBSE"],"gpt_icon":0},{"id":"2425512243","title":"BRIEF-Neubase Therapeutics Announces Receipt Of Notice From Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2425512243","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2425512243?lang=en_us&edition=fundamental","pubTime":"2024-04-06 05:40","pubTimestamp":1712353208,"startTime":"0","endTime":"0","summary":"April 5 (Reuters) - NeuBase Therapeutics Inc   :   * NEUBASE THERAPEUTICS ANNOUNCES RECEIPT OF NOTICE FROM NASDAQSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSQ","LENZ","QID","SQQQ","NQmain","BK4112","MNQmain","QQQ","LU2210150020.SGD","TQQQ","BK4585","NBSE","NDAQ","LU2210149790.SGD","QLD","BK4139",".IXIC","BK4588","LU2095319765.USD"],"gpt_icon":0},{"id":"2425516577","title":"NeuBase Therapeutics announces receipt of Nasdaq notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2425516577","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2425516577?lang=en_us&edition=fundamental","pubTime":"2024-04-06 04:21","pubTimestamp":1712348509,"startTime":"0","endTime":"0","summary":"NeuBase Therapeutics  said on Friday it had received a Nasdaq notice stating that the company was not in compliance with the stock exchange'scontinued listing requirements.According to the Nasdaq notice, NBSE failed to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, in a timely manner.The notice hasno immediate effect on the listing of the company’s common stock, NBSE added.More on NeuBase Therapeutics  Financial information for NeuBase Therapeutics","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/958260280/image_958260280.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/958260280/image_958260280.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4087679-neubase-therapeutics-announces-receipt-of-nasdaq-notice","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["QQQ","BK4585",".IXIC","NBSE","BK4588","SQQQ","LU2095319765.USD","NDAQ","NQmain","QID","BK4139","PSQ","LU2210149790.SGD","BK4112","MNQmain","TQQQ","LENZ","LU2210150020.SGD","QLD"],"gpt_icon":0},{"id":"2425515128","title":"NeuBase Therapeutics Announces Receipt of Notice from Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2425515128","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2425515128?lang=en_us&edition=fundamental","pubTime":"2024-04-06 04:05","pubTimestamp":1712347500,"startTime":"0","endTime":"0","summary":"PITTSBURGH, April 05, 2024  -- NeuBase Therapeutics, Inc.   today reported that it received a notice  onApril 4, 2024from the Listing Qualifications Department ofThe Nasdaq Stock Market LLC notifying the Company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250  as a result of its failure to file its Annual Report on Form 10-K for the fiscal year endedDecember 31, 2023 in a timely manner.This Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. Under Nasdaq rules, the Company has 60 calendar days from receipt of the Notice, or untilJune 3, 2024, to submit a plan to regain compliance with the Rule. If Nasdaq accepts the Company’s plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the Form 10-K, or untilSeptember 30, 2024, to regain compliance with the Rule.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dKFoIuXhp1sA0_PKSsyMzA--~B/aD02MDA7dz0yNDc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/819c8fa750f73cb377aa6fe55b5ff98f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dKFoIuXhp1sA0_PKSsyMzA--~B/aD02MDA7dz0yNDc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/819c8fa750f73cb377aa6fe55b5ff98f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neubase-therapeutics-announces-receipt-notice-200500065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4112","BK4139","BK4588","NQmain","NBSE","NDAQ",".IXIC","TQQQ","QQQ","QLD","BK4585","LENZ","SQQQ","LU2210150020.SGD","PSQ","LU2095319765.USD","MNQmain","QID","LU2210149790.SGD"],"gpt_icon":0},{"id":"2422641716","title":"VERI, CHEK and CZOO among mid-day movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2422641716","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2422641716?lang=en_us&edition=fundamental","pubTime":"2024-03-27 00:55","pubTimestamp":1711472148,"startTime":"0","endTime":"0","summary":"Gainers: Mesoblast Ltd  +74%. Stoke Therapeutics  +70%. Cazoo Group Ltd  +47%. Trump Media & Technology Group Corp.  +43%. Nuvation Bio  +31%. Krispy Kreme  +28%. C3is  +24%. Veritone  +25%. Check-Cap Ltd  +25%.  Reviva Pharmaceuticals Holdings  +24%.  Losers: Quhuo Ltd  -55%. NeuBase Therapeutics  -54%. Ampio Pharmaceuticals  -53%. AppTech Payments Corp  -41%. Cardlytics  -30%. M-tron Industries  -29%. GDS Holdings Limited  -24%. flyExclusive  -24%. Syntec Optics Holdings  -22%. Equillium  -21%.   More on Mid-day movers & stocks.  Veritone: Not An AI Stock To Bank On Veritone, Inc.  Q4 2023 Earnings Call Transcript Check-Cap jumps on Nobul AI business combination Veritone Non-GAAP EPS of -$0.16 in-line, revenue of $34.2M beats by $0.4M Seeking Alpha’s Quant Rating on Check-Cap","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4083881-veri-chek-and-czoo-among-mid-day-movers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4106","FLYX","BK4023","NBSE","CZOO","CDLX","BK4505","BK4082","BK4214","BK4526","BK4007","GDS","BK4209","CHEK","BK4137","AMPE","BK4227","STOK","BK4148","APCX","MESO","BK4563","EQ","QH","BK4139","BK4543","BK4585","RVPH","DNUT","BK4539","BK4588","DJT","BK4145","BK4009","CISS","BK4579","BK4529","OPTX","BK4021","BK4568","MPTI","BK4008","BK4531","NUVB","BK4122","BK4116","VERI"],"gpt_icon":0},{"id":"2422192306","title":"Nasdaq Gains Over 50 Points; US Durable Goods Orders Rise In February","url":"https://stock-news.laohu8.com/highlight/detail?id=2422192306","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2422192306?lang=en_us&edition=fundamental","pubTime":"2024-03-26 22:09","pubTimestamp":1711462177,"startTime":"0","endTime":"0","summary":"U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 50 points on Tuesday.\n\nThe Dow traded up 0.08% to 39,346.40 while the NASDAQ rose 0.39% to 16,448.92. The S&amp;P 500 also fell, dropping, 0.23% to 5,230.19.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/03/37936513/nasdaq-gains-over-50-points-us-durable-goods-orders-rise-in-february","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QQQ","OPGN","CISS","BK4137","BK4585","APCX",".IXIC","NBSE","QLD","BK4588","QH","SQQQ","LU2095319765.USD","BK4227","NDAQ","BK4106","NQmain","QID","BK4021","BK4139","PSQ","LU2210149790.SGD","BK4112","MNQmain","TQQQ","STOK","LU2210150020.SGD","PCOM","BK4122"],"gpt_icon":0},{"id":"2422616722","title":"NeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics among healthcare movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2422616722","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2422616722?lang=en_us&edition=fundamental","pubTime":"2024-03-26 22:00","pubTimestamp":1711461612,"startTime":"0","endTime":"0","summary":"Gainers: Stoke Therapeutics STOK +79%. Mesoblast ADR MESO +29%. ABVC BioPharma  +31%. Praxis Precision Medicines PRAX +25%. Check-Cap CHEK +23%.  Losers: NeuBase Therapeutics  -54%. Ampio Pharmaceuticals AMPE -51%. Tivic Health Systems TIVC -12%. Bluebird bio BLUE -13%. eFFECTOR Therapeutics EFTR -15%.  S&P 500 Health Care Sector +0.2% to 1697.44. Health Care Equipment & Services +0.34% to 1979.48. Pharmaceuticals, Biotechnology & Life Science which contributes 58% to index is +0.05% to 1385.07.  More on Health Care Select Sector SPDR  XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Johnson & Johnson, Boston Scientific least shorted stocks in S&P 500 healthcare sector for Feb-end Waters, Moderna most shorted stocks in S&P 500 health sector till Jan-end Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4083716-neubase-therapeutics-abvc-biopharma-stoke-therapeutics-among-healthcare-movers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4581","UPRO",".SPX","BK4550","NBSE","OEX","LENZ","SPXU","ABVC","BK4559","OEF","ESmain","BK4588","IVV","SH","BK4534","SDS","SSO","BK4585","BK4504","SPY","BK4139"],"gpt_icon":0},{"id":"2422694425","title":"GOEV, NBSE and FLGC among pre-market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2422694425","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2422694425?lang=en_us&edition=fundamental","pubTime":"2024-03-26 20:15","pubTimestamp":1711455352,"startTime":"0","endTime":"0","summary":"Losers: NeuBase Therapeutics  -58%. AppTech Payments Corp  -41% announces proposed underwritten public offering. Ampio Pharmaceuticals  -38% announces voluntary delisting and SEC deregistration. Tivic Health Systems  -16% after Q3 earnings release. Cardlytics  -12% on proposed $150M convertible notes offering. Dada Nexus Ltd  -11% after Q4 earnings release.  eFFECTOR Therapeutics  -8% after Q4 earnings release. Bioline Rx Ltd  -8% after FY earnings release. MAIA Biotechnology  -7% looks to raise $1.33M through a private placement. Global Mofy Metaverse Ltd  -7%. MicroAlgo  -7%. Canoo  -6%. Flora Growth Corp  -5%. Bluebird bio  -5% reports Q4 results.   More on Pre-market losers & stocks.  Canoo: Positive News Isn't Enough Canoo: Avoid After Reverse Stock Split Canoo: There Is A Glimpse Of Hope But Hold Canoo completes acquisition of manufacturing assets from Arrival Canoo's manufacturing facility gets foreign trade zone status; shares rise ~59%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4083646-goev-nbse-and-flgc-among-pre-market-losers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["APCX","BLRX","BK4009","BK4106","BK4108","BK4558","BK4578","BK4139","BK4556","BK4585","CDLX","BK4227","DADA","BK4539","BK4563","BK4007","GMM","MLGO","EFTR","GOEV","AMPE","BK4122","BK4588","TIVC","BK4155","NBSE","BK4099","FLGC","BK4134","MAIA","BK4082","BLUE","BK4183"],"gpt_icon":0},{"id":"2414060560","title":"BUZZ-NeuBase rises on plan to liquidate and distribute its assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2414060560","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2414060560?lang=en_us&edition=fundamental","pubTime":"2024-02-26 18:02","pubTimestamp":1708941727,"startTime":"0","endTime":"0","summary":"** Shares of NeuBase Therapeutics    rise ~22.2% to 87 cents premarket   ** Co said late on Friday it has decided to dissolve, liquidate and distribute to stockholders its available assets   ** The board expects to approve a formal plan of dissolution in the near future - NBSE   ** Co said it has been evaluating strategic alternatives that include an acquisition, merger, business combination, dissolution or other transaction   ** Up to last close, stock was down 85.5% in the last 12 months ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","BK4139","NBSE"],"gpt_icon":0},{"id":"2413270681","title":"NeuBase Therapeutics Plans Dissolution and Asset Liquidation","url":"https://stock-news.laohu8.com/highlight/detail?id=2413270681","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2413270681?lang=en_us&edition=fundamental","pubTime":"2024-02-24 22:56","pubTimestamp":1708786586,"startTime":"0","endTime":"0","summary":"NeuBase Therapeutics Inc (NBSE) has released an update. NeuBase Therapeutics, Inc. is set to dissolve, liquidate its assets, and distribute them to...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neubase-therapeutics-plans-dissolution-and-asset-liquidation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neubase-therapeutics-plans-dissolution-and-asset-liquidation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NBSE"],"gpt_icon":0},{"id":"2413683743","title":"BRIEF-Neubase Therapeutics To Dissolve, Liquidate And Distribute To Stockholders Its Available Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2413683743","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2413683743?lang=en_us&edition=fundamental","pubTime":"2024-02-24 07:37","pubTimestamp":1708731424,"startTime":"0","endTime":"0","summary":"Feb 23  - NeuBase Therapeutics Inc   :   * NEUBASE THERAPEUTICS- ON FEB 22, BOARD DETERMINED FOR COMPANY TO DISSOLVE, LIQUIDATE AND DISTRIBUTE TO STOCKHOLDERS ITS AVAILABLE ASSETS   * NEUBASE THERAPEUTICS INC - HAS BEEN ENGAGED IN AN EVALUATION OF POTENTIAL STRATEGIC AND OTHER ALTERNATIVES   * NEUBASE THERAPEUTICS INC - BOARD UNANIMOUSLY APPROVED LIQUIDATION AND DISSOLUTION OF COMPANY   * NEUBASE THERAPEUTICS INC -  BOARD EXPECTS TO, IN NEAR FUTURE APPROVE A FORMAL PLAN OF DISSOLUTIONSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBSE"],"gpt_icon":0},{"id":"2404676873","title":"BUZZ-NeuBase climbs after CEO change","url":"https://stock-news.laohu8.com/highlight/detail?id=2404676873","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2404676873?lang=en_us&edition=fundamental","pubTime":"2024-01-18 02:36","pubTimestamp":1705516567,"startTime":"0","endTime":"0","summary":"** Shares of biotech co NeuBase Therapeutics    rise ~4% to 62 cents, set to snap 6-day losing streak   ** Co says it terminated CEO Dietrich Stephan without cause and appointed CFO Todd Branning to the post   ** Branning has been serving as the company's finance chief since January 2022 and will continue in this role during his tenure as the interim CEO   ** Since Stephan took over as CEO in 2019, co's stock has lost almost all its value; In the last 12 months, it has fallen 89.3% ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","NBSE","BK4139"],"gpt_icon":0},{"id":"2404033695","title":"BRIEF-Neubase Therapeutics Board Terminated Employment Of Dietrich Stephan As CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2404033695","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2404033695?lang=en_us&edition=fundamental","pubTime":"2024-01-17 19:21","pubTimestamp":1705490512,"startTime":"0","endTime":"0","summary":"Jan 17  - NeuBase Therapeutics Inc   :   * NEUBASE THERAPEUTICS INC: ON JAN 12, BOARD TERMINATED EMPLOYMENT OF DIETRICH A. STEPHAN, PH.D. AS CHIEF EXECUTIVE OFFICER OF COMPANY, WITHOUT CAUSE   * NEUBASE THERAPEUTICS-  APPOINTED TODD P. BRANNING, WHO HAS SERVED AS COMPANY'S CFO SINCE JANUARY 2022, AS INTERIM CEO   * NEUBASE THERAPEUTICS INC: DIETRICH A. STEPHAN IS EXPECTED TO CONTINUE TO SERVE ON BOARDFurther company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBSE"],"gpt_icon":0},{"id":"2393313495","title":"BRIEF-Neubase Therapeutics Says Carnegie Mellon University Terminated License Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2393313495","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2393313495?lang=en_us&edition=fundamental","pubTime":"2023-12-22 19:30","pubTimestamp":1703244626,"startTime":"0","endTime":"0","summary":"Dec 22  - NeuBase Therapeutics Inc   :   * NEUBASE THERAPEUTICS INC - CARNEGIE MELLON UNIVERSITY TERMINATED LICENSE AGREEMENT   * NEUBASE THERAPEUTICS INC - DID NOT INCUR ANY EARLY TERMINATION PENALTIES IN CONNECTION WITH THE TERMINATION OF THE LICENSE AGREEMENT   * NEUBASE THERAPEUTICS INC - CMU TERMINATED LICENSE AGREEMENT IN CONNECTION WITH EXCLUSIVE, WORLDWIDE RIGHT TO PATROL TECHNOLOGYFurther company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBSE","BK4139"],"gpt_icon":0},{"id":"2392743759","title":"North American Morning Briefing: S&P 500 Eyes Record High as Rate Cut Hopes Underpin Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2392743759","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2392743759?lang=en_us&edition=fundamental","pubTime":"2023-12-19 19:00","pubTimestamp":1702983600,"startTime":"0","endTime":"0","summary":"- The Office Market Had It Hard in 2023. Next Year Looks Worse.- Bank of Japan Chief, Bucking Expectations, Avoids Talk of Rate Increase. Stock futures hovered on Tuesday as investors continued to revel in an expected loosening of monetary policy in 2024 amid a 'soft landing' for the economy.Some Fed officials in recent days appeared to push back against the market's hopes for lower borrowing costs as early as March, but equity investors seem to have shrugged off those comments, for now.Meanwhile, the Bank of Japan reminded traders that an important spigot of cheap money still remains open.The BOJ left its main interest rate at minus 0.1%, and in the accompanying news conference, Governor Ueda provided little evidence he was minded to exit the central bank's ultra-loose monetary policy anytime soon, despite inflation running above its 2% target for 19 consecutive months.Plug Power was downgraded to Underweight from Neutral at Piper Sandler and the price target on shares of the clean en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLN","PURE","RFL","US10Y.BOND","IVV","NBSE","SG9999004303.SGD","BK4585","LU0456855351.SGD","UPRO","LU0861579265.USD","LU0052756011.USD","OEF","BYFC","BK4077","CWBR","AXLA","SH","CONN","SPXU","ET","EPAC",".SPX","ACN","SDS","BK4020","SG9999018865.SGD","LU0198837287.USD","SPY","US5Y.BOND","OEX","LU0640476718.USD","FDX","BK4195","FCEL","GOOG","ESmain","US3Y.BOND","LU0742534661.SGD","LU0719512351.SGD","US30Y.BOND","US2Y.BOND","US6M.BOND","FDS","CAMP","US7Y.BOND","GOOGL","SSO","LU0320765059.SGD","US12M.BOND"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neubasetherapeutics.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":-0.4407},{"period":"ytd","weight":-0.4893}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":-0.051606},{"month":2,"riseRate":0.545455,"avgChangeRate":-0.020666},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.134531},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.107823},{"month":5,"riseRate":0.272727,"avgChangeRate":-0.005084},{"month":6,"riseRate":0.545455,"avgChangeRate":-0.028902},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.021459},{"month":8,"riseRate":0.416667,"avgChangeRate":-0.039189},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.043762},{"month":10,"riseRate":0.5,"avgChangeRate":-0.040989},{"month":11,"riseRate":0.5,"avgChangeRate":0.102936},{"month":12,"riseRate":0.363636,"avgChangeRate":0.020535}],"exchange":"NASDAQ","name":"NeuBase Therapeutics Inc.","nameEN":"NeuBase Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NeuBase Therapeutics Inc.(NBSE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NeuBase Therapeutics Inc.(NBSE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NeuBase Therapeutics Inc.,NBSE,NeuBase Therapeutics Inc.股票,NeuBase Therapeutics Inc.股票老虎,NeuBase Therapeutics Inc.股票老虎国际,NeuBase Therapeutics Inc.行情,NeuBase Therapeutics Inc.股票行情,NeuBase Therapeutics Inc.股价,NeuBase Therapeutics Inc.股市,NeuBase Therapeutics Inc.股票价格,NeuBase Therapeutics Inc.股票交易,NeuBase Therapeutics Inc.股票购买,NeuBase Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NeuBase Therapeutics Inc.(NBSE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NeuBase Therapeutics Inc.(NBSE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction